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Abstract
The United States Food and Drug Administration (FDA) approved two b-adrenergic agonists (bAA) for in-feed
administration to cattle fed in confinement for human consumption. Anecdotal reports have generated concern that
administration of bAA might be associated with an increased incidence of cattle deaths. Our objectives, therefore, were to a)
quantify the association between bAA administration and mortality in feedlot cattle, and b) explore those variables that may
confound or modify this association. Three datasets were acquired for analysis: one included information from randomized
and controlled clinical trials of the bAA ractopamine hydrochloride, while the other two were observational data on
zilpaterol hydrochloride administration to large numbers of cattle housed, fed, and cared for using routine commercial
production practices in the U.S. Various population and time at-risk models were developed to explore potential bAA
relationships with mortality, as well as the extent of confounding and effect modification. Measures of effect were relatively
consistent across datasets and models in that the cumulative risk and incidence rate of death was 75 to 90% greater in
animals administered the bAA compared to contemporaneous controls. During the exposure period, 40 to 50% of deaths
among groups administered the bAA were attributed to administration of the drug. None of the available covariates
meaningfully confounded the relationship between bAA and increased mortality. Only month of slaughter, presumably a
proxy for climate, consistently modified the effect in that the biological association was generally greatest during the
warmer months of the year. While death is a rare event in feedlot cattle, the data reported herein provide compelling
evidence that mortality is nevertheless increased in response to administration of FDA-approved bAA and represents a
heretofore unquantified adverse drug event.
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Introduction
The United States Food and Drug Administration (FDA)
approved two b-adrenergic agonists (bAA) for in-feed administra-
tion to cattle that are fed in confinement (i.e., typically feedlot
operations) for human consumption [1,2]. When administered
according to label directions, bAA result in well-characterized and
predictable improvements in the rate and efficiency of weight gain,
as well as increased leanness and yield of edible products derived
from beef carcasses [3–7]. Ractopamine hydrochloride (RH) was
the first bAA approved in cattle; further, RH may be used in a
variety of dosages and has also been approved for administration
to swine and turkeys. Ractopamine hydrochloride is included in
cattle feed during the final 28 to 42 days of the fattening period.
Zilpaterol hydrochloride (ZH), the second bAA approved by the
FDA, may only be used at a single rate of inclusion in cattle feeds.
It is included in cattle feed for 20 to 40 days prior to slaughter;
however, in contrast to RH, a 3-day period during which ZH may
not be administered must be observed prior to shipment to the
abattoir (i.e., slaughter withholding).
In addition to their production uses in food-animal production,
b-adrenergic agonists are routinely used in human clinical
medicine for various conditions such as acute therapeutic
intervention and maintenance care of asthma and chronic
obstructive pulmonary disease (i.e., COPD). In human clinical
medicine, these drugs are not innocuous in that side effects (or
adverse unintended consequences) of approved medical uses of
bAA have been observed and include an increased risk of asthma
exacerbations and hospitalizations, arrhythmias, myocardial
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infarction, and death [8–12]. Unintended consequences have also
been observed with bAA use in several animal species. For
example, observations both in non-ruminant and ruminant species
indicate that administration of bAA is associated, albeit somewhat
inconsistently, with elevated heart rates, body temperature,
physical activity, lameness or foot lesions, and aggression [13–
18]. Given the widespread distribution of b-adrenoreceptors in the
body, some of these unintended consequences, such as elevated
heart rate, might (or ought to) be expected with bAA administra-
tion.
With some similarity to observations of increased risk of
mortality associated with use of certain bAA in human clinical
medicine [9,19], unpublished reports from some end-users of RH
and ZH indicated the potential for an increase in mortality in
cattle associated with FDA-approved administration of bAA.
Mortality in feedlot cattle represents a clear and meaningful
economic loss to producers. Death loss also raises broader societal
concerns about the welfare of animals fed bAA in that progression
from a healthy status to death may include in pain and suffering in
affected animals. If a relationship between bAA administration
and increased risk of mortality exists, it ought to stimulate
discussion of the pros and cons of the use of drugs approved purely
to improve the efficiencies of production yet offering no offsetting
health benefits to the animals. As an example, some antibiotics are
believed to improve production efficiency, at least in part, by
controlling or preventing subclinical disease. To our knowledge,
no beneficial ‘side-effect’ favoring improved health or welfare, or
control or prevention of disease in response to FDA-approved
bAA administration in cattle is believed to exist. Our objectives,
therefore, were to: a) quantify the association between bAA
administration and mortality in feedlot cattle, and b) explore those
variables that may confound or modify this association.
Methods
Three confidential datasets were received either through
solicitation by the first author in the case of RH or following
requests for analytical support from the owners of the data (i.e.,
feedlot operators) in the case of ZH. The authors adhere to all the
PLOS ONE policies on sharing data and materials. Different
models were constructed and where possible and appropriate, a
number of covariates (as potential and plausible confounders and
effect modifiers) were evaluated. Datasets analyzed included both
experimental trials (i.e., clinical trials involving randomized
treatment allocation) and observational studies (i.e., treatment
allocation was determined by factors other than a random
process).
Description of Datasets
The first dataset (hereafter 4-company RH dataset) included
information concerning administration of RH. A convenience
sample of cattle-feeding companies was contacted to evaluate
whether or not they had performed field-based experiments of RH
administration and, if so, to ascertain their willingness to provide
their data for further analysis. Inclusion criteria included: a)
experimental observations of RH administered to cattle pens
according to label directions so as to provide a target dose of
200 mg/animal/day for the 28 to 42 days immediately prior to
shipment to the abattoir, b) inclusion of appropriate contempo-
raneous control pens, and c) randomization performed either at
the group level, or at the individual level. Groups were then
classified as either unexposed in that all animals within the group
were fed the usual fattening diet, or else as exposed in that all
animals within the group were fed the usual fattening diet with RH
incorporated to provide the target dose.
This first aggregated dataset included information from four
companies and collectively included 12 separate randomized
experiments. All experiments used a randomized block design in
that there were at least 2 groups per block, i.e., one administered
RH and the other not. These data included information suitable
for analysis on a total of 79,171 cattle. These animals were
aggregated into 509 groups that averaged 155.5 (standard
deviation [SD]= 70.9, minimum [MIN]= 42, maximum
[MAX]= 381) animals per group. The number of studies and
groups varied by company in that company A provided data on
1,510 animals that were enrolled in 1 study and housed in 24
groups, company B provided data on 5,696 animals across 3
studies and housed in 52 groups, company C provided data on
62,379 animals across 3 studies and housed in 329 groups, and
company D provided data on 9,586 animals across 5 studies and
housed in a total of 104 groups. The combined 6 studies
conducted by companies B and C were conducted in 6 different
feedlots whereas the 5 studies of company D were all conducted in
the same feedlot. The vast majority of cattle were steers (i.e.,
castrated males; n = 72,868 in 441 groups) with the balance being
females (i.e., heifers; n = 6,303 in 68 groups). Heifers were
exclusively enrolled as the study population in 3 of the 5
experiments of company D.
The second dataset (multi-feedlot ZH dataset) concerned
administration of ZH and included observational data from nine
feedlots. Data on 722,704 animals were provided and the cattle
were housed in 3,110 groups of an average size of 232.4 animals
per group (SD=91.3, MIN=32, MAX=943). Out of these
animals, 79.3% (n= 573,076) were steers and 20.7% (n= 149,628)
were heifers. The at-risk period of interest for exposed animals
included both the period during which ZH was administered as well
as the slaughter-withholding period. This slaughter-withholding
period must be a minimum of 3 days but may be longer depending
on various marketing strategies used by the feedlots. For the
unexposed population in the multi-feedlot ZH dataset, the at-risk
period was calculated by including the typical number of days ZH
was administered to the exposed cohort and the typical slaughter-
withholding period. Based on the observed and calculated at-risk
periods for the exposed and unexposed cohorts, respectively, the
mean at-risk periods consisted of the final 29.4 and 29.2 days prior
to shipment, respectively. The data were unbalanced in that there
were 2,775 groups comprised of 637,339 animals administered ZH
(i.e., exposed cohort) and 335 groups comprised of 85,365 animals
that served as comparative controls (i.e., unexposed cohort). The
mean group sizes were 229.7 (SD=90.7, MIN=32, MAX=943)
and 254 (SD=94.0, MIN=55, MAX=610), respectively. The
number of animals per feedlot for which data were provided varied
from 61,059 to 123,679. Heifers were represented in the data from 8
of the 9 feedlots.
The third dataset (single-feedlot ZH dataset) included
observational data on 149,636 animals that were housed in 835
groups in a single feedlot. Of the population at risk, 88.7%
(n= 132,725) were steers and 11.3% (n= 16,911) were heifers. The
data were more balanced than the multi-feedlot ZH dataset in that
56.1% of the cattle (n = 83,865 in 470 groups) were administered
ZH (i.e., exposed cohort) whereas 43.9% of the cattle (n = 65,711
in 365 groups) served as the contemporaneous control cohort. The
mean group sizes were 178.4 (SD=76.3, MIN=30, MAX=352)
and 180.2 (SD=63.9, MIN=54, MAX=382), respectively. The
feedlot was managed in such a way that ZH was administered 21
days prior to shipment and a 3-day withdrawal period was
observed. This 24-day period was considered the at-risk period.
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Consequently, the final 24 days prior to shipment were considered
the comparative at-risk period for those animals not administered
ZH.
Data Analyses
The primary outcome variable of interest across all datasets was
the number of animals that died in each group during the at-risk
period (consequently, the group may be considered the experi-
mental unit of interest). This outcome variable, therefore,
represents a count response and the approaches described herein
to model count data within groups in which the outcome may be
clustered have been described [20–23]. Two offset variables were
used as denominators in the various statistical models. The first
was the natural logarithm of the population within a group (i.e.,
the at-risk population) at the start of the exposure period; the use
of this offset allows calculation of model-adjusted estimates of the
proportion the population at risk that died within each cohort
[20]. Where the at-risk period varied across groups, i.e., in the 4-
company RH and multi-feedlot ZH datasets, the natural logarithm
of time at-risk was used (in other words, the total number of cattle-
days within a group during the period of interest); the use of this
offset allows calculation of model-adjusted estimates of the
incidence of death (i.e., deaths per unit time) within each cohort
[20]. Because information on the day during the at-risk period that
individual animals died was only available for Company C in the
RH dataset, a uniform approach to estimating time at risk
(expressed as cattle-days) was used for the 4-company RH and
multi-feedlot ZH datasets. Time at risk was estimated as a function
of the at-risk period (days) multiplied by the population at risk. To
account for withdrawals due to death, half of the total possible
days at-risk was subtracted from the group’s time at risk for each
animal that died within the group.
Consistent across all datasets, therefore, were deaths within a
group, whether they were administered a bAA or not, and
population at risk. In addition, for the 4-company RH and multi-
feedlot ZH datasets, time at risk was calculated using a common
approach. Generalized linear mixed models were constructed
using commercially available statistical analysis software (SAS
System for Windows release 9.3, SAS Institute, Cary, NC) and
parameterized similarly across datasets to account for the
hierarchical nature of the data. A Poisson distribution was used
with a log-link function. In all models, a group-level term was
forced into the model to account for potential over-dispersion of
the data (i.e., extra-Poisson variation). In the model of the 4-
company RH dataset, random intercept terms were included for
company, study within company, and block within study. In the
multi-feedlot ZH dataset, a random intercept term was included to
account for potential clustering of the outcome within feedlots. To
explore potential modification of bAA effect on death loss across
companies in the 4-company RH dataset and across feedlots in the
multi-feedlot ZH dataset, the highest-level random-intercept term
was changed from a random effect to a fixed effect to explore the
interaction with exposure. Because of model convergence issues
due to sparsely populated cells in the former dataset, when
evaluating the interaction of feedlot and RH administration, data
from company A was dropped from the model (i.e., n = 1,510
animals in 24 groups where no deaths were reported in either
cohort).
Covariates were variably recorded across the three datasets. For
example, within the 4-company RH dataset, the number of deaths
within a group prior to exposure was relatively consistently
recorded whereas month of shipment was only recorded for
Company C. Further, in the multi-feedlot ZH dataset, a variety of
covariates were consistently recorded and included: sex of the
animals within a group, percentage of a group that died prior to
the at-risk period, percentage of a group that were treated prior to
the at-risk period, percentage of cattle within a group that had a
predominantly black hide, mean carcass weight of the surviving
animals that were shipped to slaughter, and month in which the
at-risk period ended (i.e., animals were shipped to an abattoir for
slaughter). However, in the single-feedlot ZH dataset only sex of
the animal and the month in which the animals were shipped to an
abattoir for slaughter were available for analysis. For each dataset,
therefore, covariates that could potentially confound or modify the
association between bAA use and death loss were evaluated in
univariate models to test their association with mortality. Model
structures were similar to those described above. Covariates with P
values less than or equal to 0.20 were included as fixed effects in
multivariable models that included main effects (i.e., potential
confounders) and terms for the interaction of each of these main
effects with exposure to bAA (i.e., effect-measure modifiers). While
maintaining hierarchy within variables, terms were removed from
the model in a backward, stepwise manner using a=0.10 level of
significance for retention. For all models, measures of burden
(proportion of population at risk and incidence of mortality per
time at risk) and measures of effect (cumulative relative risk [RR]
and incidence rate ratio [IRR], respectively) were computed from
the model estimates and presented with their 95% confidence
limits (CL) and P values where appropriate.
In addition to the primary outcome of mortality, secondary
outcomes were available for both the multi-feedlot ZH and single-
feedlot ZH datasets. Secondary count-based outcomes included
number of animals treated for illness during the at-risk period and
the number of carcasses that were classified as dark, firm and dry
(which is colloquially referred to as dark cutter in the beef cattle
industry). In addition, the proportion of cattle that could not be
shipped to slaughter because they were within a slaughter-
withholding period at the time the rest of the group was shipped
was available in the single-feedlot dataset. This so-called medicine
hold results from administration of a therapeutic drug, such as an
injectable antimicrobial drug to treat bacterial bronchopneumo-
nia; most such FDA-approved antimicrobial drugs have slaughter-
withholding periods and these must be observed prior to shipment
to slaughter for human consumption.
To explore the extent of unexplained model variation attribut-
able to the levels of company and study within company, a multi-
level, hierarchical model was constructed for the 4-company RH
dataset using commercially available software (MLwiN 2.26,
Centre for Multilevel Modelling, University of Bristol, Bristol,
UK). Four levels of organization were included in the model:
company, study within company, block within study, and group
within block; generalized linear mixed models within a Poisson
distribution were constructed. The dependent and offset variables
were those described above and RH administration was the
independent variable of interest. After accounting for RH
administration as a fixed effect in the model, unexplained variation
was partitioned to the highest 3 level terms (i.e., level 1 variance
was not calculated given the assumptions of the Poisson model)
[22]. Model estimation was performed using reweighted iterative
generalized least squares and 2nd-order penalized quasi-likelihood
approximation, while allowing for over-dispersion of the data [24].
Multivariable semi-parametric survival analysis was performed
on the data provided by Company C owing to the rich level of
detail available (Stata version 12.1, Stata Corp., College Station,
TX). The multivariable model accounted for fixed effects of study,
month of shipment to slaughter, prior mortality events experi-
enced within the cohort, and exposure to RH. In addition, the
model accounted for the shared frailty experience of animals
Mortality in Cattle Administered b Agonists
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within each group. Backwards elimination was employed to yield
the final model (accounting for potential confounding variables
and effect modifiers) and the importance of the shared group
frailty was determined using the parameter Theta.
Results
4-company RH Dataset
Overall, 0.27% (n= 211) of the 79,171 cattle died during the at-
risk period (Table 1). After accounting for various levels of
clustering, the estimates of cumulative risk and the incidence rate
of death were 0.26% (95% confidence limits [CL]= 0.16, 0.40)
and 0.86 (95% CL=0.58, 1.30) deaths per 10,000 cattle days,
respectively. Model-adjusted estimates of risk and incidence of
death for cattle administered RH were 0.34% (95% CL=0.25,
0.45) and 1.12 (95% CL=0.85, 1.45) deaths per 10,000 cattle days
at risk, respectively. For cattle not administered RH, risk and
incidence of death were 0.18% (95% CL=0.13, 0.25) and 0.59
(95% CL=0.43, 0.83) deaths per 10,000 cattle days, respectively.
After controlling for clustering within company, study, block
and group, cattle administered RH were 91% more likely to die
than control animals during the at-risk period (RR=1.90 [95%
CL=1.38, 2.60]; P,0.01). A very similar measure of effect was
observed for the incidence rate ratio (IRR=1.90 [95% CL=1.38,
2.61]; P,0.01). The only potential covariate collected across
multiple studies was the number of animals that died in each group
prior to the at-risk period. This variable neither modified the effect
of exposure on mortality (P=0.77) nor did it confound the
association between bAA and increased death loss (P=0.63).
There was no evidence that the association between RH
administration and increased death loss varied across the 3
companies that supplied data in which at least one death was
observed (P=0.66; Figure 1). Moreover, in the multilevel
hierarchical model that included all 4 companies, there was no
unexplained variation attributed to unmeasured factors across
companies (model variance = 0.00 [SE= 0.00]). At lower levels of
organization, the unexplained model variation was 4-fold greater
among blocks within studies (model variance = 0.169 [SE= 0.120])
than among studies within companies (model variance = 0.048
[SE=0.072]).
Company C provided information on 167 deaths across
1,983,564 animal-days and within this company, the incidence
of death was 83% greater among those animals administered RH
compared to controls (IRR=1.83; 95% CL=1.32, 2.56; P,0.01).
A graphical representation of the unadjusted Kaplan-Meier non-
parametric survival experiences for each set of treatment cohorts is
presented in Figure 2. The smoothed instantaneous force of
mortality for each cohort set (i.e., the hazard function [h(t)]) is
presented in Figure 3 and suggests that the constant hazard
assumption was met for approximately the first 25–28 days of the
at risk period. Moreover, the proportional hazards assumption was
met throughout the entire at-risk period. In addition, the pen-level
mortality rate prior to exposure was evaluated as a covariate but
was neither associated with the incidence of death during exposure
(P=0.61), nor did this variable confound the relation between
exposure to RH and survivor function. Importantly, the multi-
variable adjusted treatment hazard ratio (HR) of 2.00 (95%
CL=1.36, 2.96; P,0.01) was greater than that observed when the
other significant covariates (i.e., fixed effects of feedlot and month
of slaughter) and the shared frailties of group were ignored.
Because the force of mortality (hazard) was relatively constant over
time, the HR is comparable to IRR; the observed IRR was 1.83
and was included within the 95% confidence interval of the HR.
Multi-feedlot ZH Dataset
Of the 722,704 cattle at risk, 0.51% (n= 3,657) of animals died
during the exposure period (Table 1). After accounting for feedlot-
and group-level clustering, the estimates of risk and incidence of
death were 0.50% (95% CL=0.44, 0.57) and 1.68 (95%
CL=1.51, 1.86) deaths per 10,000 animal-days, respectively.
Model-adjusted estimates of the risk and incidence of death for
cattle administered ZH were 0.53% (95% CL=0.47, 0.59) and
1.77 (95% CL=1.62, 1.92) deaths per 10,000 animal-days,
respectively. Model-adjusted estimates among the unexposed
cohort were 0.30 (95% CL=0.25, 0.36) and 1.01 (95%
CL=0.85, 1.19) deaths per 10,000 animal-days, respectively.
After adjusting for the various levels of clustering, administration
of ZH was associated with a significant increase in the likelihood of
death (RR=1.76 [95% CL=1.50, 2.05]; P,0.01). When time at
risk during the exposure period was used as the offset variable
instead of population at risk, the measure of effect was similar in
that the IRR was 1.75 (95% CL=1.50, 2.05; P,0.01).
Covariates included in the multivariable model as main effects
(i.e., potential confounders) along with terms representing their
interactions with exposure to ZH (i.e., effect modifiers) included
(Table 2):
N Sex of the animals within a group,
N Percentage of a group that died prior to the at-risk period,
N Percentage of a group that were treated prior to the at-risk
period,
N Percentage of cattle within a group that had a predominantly
black hide,
N Mean carcass weight of the surviving animals that were
shipped to slaughter, and
N Month in which the at-risk period ended (i.e., animals were
shipped to an abattoir for slaughter).
Of the main effect terms, only percentage of a group that died
prior to the at-risk period and mean carcass weight of animals
shipped to slaughter were removed from the final model. The only
effect modifier (i.e., interaction term) that was retained was month
in which the animals were shipped to the abattoir (P=0.07). While
controlling for the other covariates, RR estimates were 1.17 (95%
CL=0.64, 2.14; P=0.60; Figure 4); 1.56 (95% CL=0.86, 2.82;
P=0.15); 1.23 (95% CL=0.87, 1.73; P=0.24); 2.69 (95%
CL=1.86, 3.90; P,0.01); 1.80 (95% CL=1.28, 2.53; P,0.01);
1.86 (95% CL=1.42, 2.43; P,0.01) and 1.71 (95% CL=1.18,
2.49; P=0.01) for March, April, May, June, July, August, and
September, respectively.
Averaged across the means of all other terms in the model,
treatment remained significantly associated with mortality
(RR=1.66 [95% CL=1.40, 1.96]; P,0.01). Thus, its effect did
not appear to be confounded to any meaningful extent by other
variables (those listed in bullet form above) in that the measure of
effect from the multivariable model was similar to the reduced
model in which only exposure was included as a fixed effect.
The same set of covariates listed above were associated with the
incidence rate of death in univariate models; that is, the models in
which when time at risk was included as the offset variable. These
variables were subsequently included as covariates (main effects
and effect modifiers) in the multivariable model of the incidence of
death. While the same main effects were retained in the final
model as those for the population at-risk model, no effect modifiers
were retained in the final model (i.e., P.0.14 for all interaction
terms). Controlling for the covariates that remained in the model
(i.e., sex, month shipped to slaughter, percent of the group with a
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black hide, and percent of pen treated prior to the at-risk period),
the incidence of death was 80% greater in animals administered
ZH than the comparative control cohort (IRR=1.80 [95%
CL=1.55, 2.10]; P,0.01). The association between incidence
rate of death and administration of bAA, therefore, did not appear
to be confounded by the covariates available for analysis.
There was little evidence of feedlot-to-feedlot variation in the
association between ZH and increased risk of death. In the
population at-risk model, for example, the covariance parameter
was much greater at the group-level (1.14 [SE= 0.03]) than that
observed at the feedlot-level (0.04 [SE=0.02]). In the alternative
model that treated feedlot and its interaction with exposure as ZH
fixed effects, there was no evidence that the association between
administration of ZH and increased mortality was modified by
which feedlot the animals were housed in either the population at
risk (P=0.16) or time at risk models (P=0.26; Figure 1).
Two secondary outcomes were available for analysis (Table 3).
Cattle administered ZH were 33% more likely (RR=1.33 [95%
CL=1.18, 1.50]; P,0.01) to require treatment for illness during
the at-risk period than animals not administered ZH. In addition,
an association between ZH administration and an increased
likelihood of the animal’s beef being classified as dark, firm and dry
Figure 1. Association between b-adrenergic agonist administration and mortality. Model-adjusted estimates of incidence of death per
10,000 animal-days for cattle administered either ractopamine hydrochloride (RH – graph A) or zilpaterol hydrochloride (ZH – graph B) compared to a
diet without a beta agonist. No deaths were reported for Company A (graph A) and rates for Feedlot I (graph B) were non-estimable. P values are
those associated with interaction term for exposure by company (graph A) or feedlot (graph B). Bars represent upper 95% confidence limit.
doi:10.1371/journal.pone.0091177.g001
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was detected (Table 4); however, this latter association was
modified by the sex of the animal (P=0.01). The carcasses derived
from steers administered ZH were 2.31 times more likely to be
classified as dark, firm and dry compared to carcasses of steers not
administered ZH (RR=2.31 [95% CL=1.77, 3.02]; P,0.01). Of
the steer carcasses, 1.87 and 0.81%, of those administered ZH and
the unexposed cohort, respectively, were classified as dark, firm and
dry. No such association was observed with treatment among the
carcasses derived from heifers (P=0.36); of the heifer carcasses,
1.30 and 1.07%, of those administered ZH and the unexposed
cohort, respectively, were classified as dark, firm and dry.
Figure 2. Survival analysis for cattle administered a b-adrenergic agonist. Kaplan-Meier non-parametric (actual) and Cox proportional
hazards (predicted) survivor functions (S(t)) for cattle administered a diet containing ractopamine hydrochloride (RH) compared to a diet without RH
in Company C.
doi:10.1371/journal.pone.0091177.g002
Figure 3. Force of mortality among cattle administered a b-adrenergic agonist. Empirical cumulative hazard function (H(t)) and 95%
confidence intervals (during those time periods where mortalities occurred) for cattle administered a diet containing ractopamine hydrochloride (RH)
compared to a diet without RH in Company C.
doi:10.1371/journal.pone.0091177.g003
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Single-feedlot ZH Dataset
Of the 149,636 cattle at risk, 0.38% (n= 571) died during the
24-day exposure period and after accounting for potential over-
dispersion in the data, the 95% CL of this estimate were 0.35%
and 0.42%, respectively (Table 1). Model-adjusted estimates of the
risk of death among those administered ZH and the comparative
cohort were 0.48% (95% CL=0.43, 0.53) and 0.26% (95%
CL=0.22, 0.31), respectively. After adjusting for clustering,
administration of ZH was associated with an 85% increase in
the risk of death (RR=1.85 [95% CL=1.51, 2.27]; P,0.01)
during the at-risk period. Mortalities were classified as attributable
to conditions either of the respiratory system or of the digestive
system (this latter category also included all other attributable
causes of death). After adjusting for clustering, administration of
ZH was associated with an increase in the risk of death attributable
to conditions of the respiratory (RR=2.15 [95% CL=1.60, 2.91];
P,0.01) and digestive (RR=1.82 [95% CL=1.31, 2.52]; P,0.01)
systems.
Overall mortality was associated with sex and month of
slaughter; in addition to their interactions with exposure, these
Figure 4. Seasonal modification of the association between b-
adrenergic agonist administration and mortality. Model-adjusted
estimates of the percentage of cattle that died among groups of
animals administered zilpaterol hydrochloride (ZH) compared to a diet
without ZH by month in which they were shipped to slaughter. Graph A
represents 722,704 animals housed in 9 feedlots and graph B represents
149,636 animals housed in a single feedlot.
doi:10.1371/journal.pone.0091177.g004
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main effects were included in a final multivariable model. The
final model included sex, month and the interaction between ZH
exposure and month. Averaged across other variables, animals
exposed to ZH were 56% more likely to die than animals in the
comparative cohort (RR=1.56 [95% CL=1.25, 1.95]; P,0.01).
However, this effect was modified by the month in which animals
were shipped to the abattoir (P=0.01). Model-adjusted RR
estimates were 3.06 (P=0.01; Figure 4); 1.83 (P=0.07); 2.30
(P,0.01); 2.42 (P,0.01); 1.72 (P=0.01); 0.85 (P=0.58), 0.80
(P=0.47) and 0.97 (P=0.94) for April, May, June, July, August,
September, October, and November, respectively.
A number of secondary outcomes were available for analysis in
this third dataset (Table 3). Animals administered ZH were 23%
more likely to require treatment for any condition during the
exposure period (RR=1.23 [95% CL=1.07, 1.41]; P,0.01). The
likelihood of treatment, however, varied by the body system to
which the clinical signs were attributed. Animals were 34% less
likely to require treatment for conditions attributed to the digestive
system (RR=0.66 [95% CL=0.55, 0.79]; P,0.01) but 2.3 times
more likely to require treatment for conditions attributed to the
respiratory system (RR=2.31 [95% CL=1.89, 2.83]; P,0.01). In
addition, animals administered ZH were 2.3 times more likely to
require more than a single treatment regimen for respiratory
disease than contemporaneous controls (RR=2.34 [95%
CL=1.82, 3.04]; P,0.01). As a consequence of the increased
burden of treatments in animals administered ZH, there was a 3-
fold increase in the percentage of animals subject to a slaughter
withholding period at the time the rest of their group was shipped
to slaughter (RR=3.00 [95% CL=2.31, 3.90]; P,0.01). Those
animals that could not be shipped to slaughter with their
contemporaries were dispersed across many groups rather than
clustered within a few; that is, 50.0% of groups administered ZH
had one or more animals that could not be shipped with the rest of
their group compared to 25.8% of groups not administered ZH.
Once at the abattoir, a greater percentage of carcasses from ZH
administered cattle (1.59%) were classified as dark, firm and dry
(Table 4), compared to those carcasses from animals not
administered ZH (0.53%; RR=3.02 [95% CL=2.35, 3.89]; P,
0.01). As opposed to the 9-feedlot dataset, sex was neither a
modifier of this association (P=0.21) nor a significant covariate
(P=0.34).
Discussion
Death is a relatively rare event in feedlot cattle [25,26]. Even so,
the data presented herein provide compelling evidence that
administration of FDA-approved bAA to cattle increased both
the cumulative incidence (risk) and incidence rate of death. The
various measures of effect used to explore the relationship between
bAA and mortality, i.e., RR, IRR and HR where applicable, were
similar across the multiple datasets that included both randomized
field trials and population-based observational data. The attrib-
utable fraction (AF), a measure of the proportion of deaths
attributable to bAA administration among those cattle in the
exposed cohort, varied little from dataset to dataset, remaining
relatively constant at 40–50%.
Of considerable practical interest among those responsible for
the care and well-being of cattle intended for slaughter for human
consumption is identification of variables that could be exploited
to help select or manage groups of cattle for which bAA drugs
might be contraindicated. The most consistent modifier of the
biological association between bAA administration and mortality
was month of year (Figure 4). In the multi-feedlot ZH data set,
month was statistically detected as an effect modifier in one model
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(i.e., population at-risk) but not in the other model (i.e., time at-
risk). However, in the latter model, the observed P value (0.14)
provided some, albeit weak, evidence of variation in the
association across months. In the single-feedlot ZH dataset, month
was again detected as a significant modifier of the association
between bAA administration and mortality (P=0.01). Further-
more, the consistency of the temporal pattern of this association
across the multi- and single-feedlot ZH datasets (Figure 4) provides
compelling reasons to explore seasonal factors that might modify
the effect of bAA administration on mortality. By this we mean
that month is clearly a proxy for other variables with the most
probable being thermal heat index. Given the variation in the
measure of effect across months, at least for ZH, it seems plausible
that greater heat indices may have contributed to a dispropor-
tionate increase in the risk of death among animals administered
bAA when compared to those not administered this synthetic
hormone. It was not possible, however, to test this association in
our analysis; clearly this warrants additional prospective explora-
tion. If month is indeed a proxy for a causal biological interaction
between some measure of heat index and bAA administration,
then mitigation strategies, as yet unknown, need to be developed
for a substantial proportion of the year in that a significant
relationship was detected in those cattle shipped for slaughter
beginning in April (in the single-feedlot ZH dataset) and for those
cattle shipped for slaughter through September (in the multi-
feedlot ZH dataset).
Force of mortality, which is sometimes referred to as the hazard
function, is an instantaneous measure of the risk of death in the
next time period, conditioned on having survived to the present.
This measure was greater for those animals administered RH than
unexposed animals and was relatively constant for both groups
across the majority of the exposure period for company C. The
apparent late-stage increase (Figure 3) in the hazard function
among the RH-treated groups of animals, when compared to the
control groups of animals, did not lead to a violation of the
proportional hazards assumption of the semi-parametric survival
analysis. However, this increase appeared quite marked and bears
further examination in any follow-up research. Unfortunately,
days of exposure for each animal that died were only available for
company C and included 3 large randomized trials of RH of
62,379 animals. Consequently, the force of mortality for those
cattle administered ZH could not be evaluated.
A number of broad hypotheses might explain the observed
association of bAA drug administration and increased mortality.
The first potential hypothesis is that other unmeasured confound-
ing variable(s) gave rise to a spurious relationship. For example, in
the ZH datasets, the contemporaneous control cohorts consisted of
those animals not administered a bAA. There are various reasons
why these animals were not fed a bAA. For example, they may
have been destined for a marketing program that precluded the
use of a bAA or they were deemed not suitable for bAA
administration (e.g., their body weight was sufficient enough that if
fed a bAA hormone, their carcass weights would have been
excessive). While it is possible that these unmeasured variables
confounded the association of bAA use and increased death loss, it
seems highly improbable given the strength of association and
consistency of effect across feedlots, datasets, and the covariates
evaluated in the models. This possibility seems even more
implausible in the dataset involving RH. Each of the 12 studies
included randomized allocation of animals or groups to the
exposed or unexposed cohorts. One of the major benefits of
randomization is the unbiased distribution of unmeasured
confounders among the treatment groups. Furthermore, apart
from company A in which no deaths in either cohort were
reported, statistical variation among the measured associations of
RH administration and mortality was not detected among
companies B, C, and D. In addition, no statistical variation in
the association between bAA and increased death loss was
observed across feedlots in the multi-feedlot ZH dataset. This
association, therefore, was relatively consistent and predictable
from operation to operation despite unmeasured variation in
farming practices and other attributes such as feedlot size,
geographical location, animal husbandry, and cattle diets.
A second and related hypothesis is that the association was not
necessarily due to the drug itself; rather, the association might have
been a consequence of those management changes required to
administer the bAA in the ration. Such collinearity of effects is
virtually impossible to disentangle without purposively designing a
study (e.g., a cross-over design) to deal with the phenomenon. For
example, although not available in the data described herein, it is
possible that the time at which feed was delivered changed for
those animals administered a bAA. That is, most modern cattle
feedlots have developed strategies to provide a consistent diet in a
consistent and timely manner to the cattle. In this scheme, the
amount of feed delivered is expected to be consumed within 24
hours. Because a minority of groups of cattle are fed bAA at any
one time in an feedlot, one management strategy might be to feed
the unexposed cattle first and subsequently feed the ration
containing the bAA later in the day. If so, this strategy could
have resulted in a relatively sudden change in the time at which
the bAA-exposed cattle were fed (possibly up to a 2-hour delay for
example). While cattle tend to adapt relatively quickly to changes
in routine, such a change might have initially resulted in cattle that
were hungry and thus over-consumed readily fermentable
carbohydrates. However, the observed force of mortality was
relatively constant over the exposure period (i.e., from day 0 up to
42). The feedlots that supplied data for the 2 observational datasets
have had a number of years of experience in feeding the FDA-
approved bAA and have had the opportunity to develop and
adopt management strategies to minimize changes in routine.
A third hypothesis is that the bAA hormones themselves are
causally associated with the increased mortality. Clearly, the
measure of effects are relatively strong and consistent across the
datasets; yet, given that the RH studies were not purposefully
designed to investigate an association with mortality and the
observational nature of the ZH data, it is difficult to definitively
establish a causal relationship nor to identify the mechanistic
explanations. However, evidence supporting adverse drug events
can be drawn from the aggregated observations of bAA
administration in human medicine. For example, authors of
various studies that included randomized clinical trials and an
FDA-performed meta-analysis of the available data, have
concluded that long-acting b2 adrenergic agonists used for asthma
contribute to an increased risk of severe asthma events and death
[8,9,11,19]. While this association might be somewhat ameliorated
by the inclusion of a corticosteroid, the FDA determined this was a
class effect and now requires a boxed warning to be included on
the labels of all long-acting bAA intended to be administered
routinely, e.g., daily for the control of asthma. Furthermore, in the
datasets of ZH in which risk of treatment was available, exposed
animals were more likely to require treatment during the at-risk
period than unexposed animals.
Others have reported an increased risk of myocardial disease in
certain patients administered bAA drugs [12]. If a similar
association occurs in cattle, one might expect metabolic markers
of such an event, elevated creatine phosphokinase (CPK) for
example [27]. Indeed, ZH administration is associated with
increased serum CPK [2]; unfortunately the isoform(s) were not
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reported so it is uncertain if the elevated serum CPK resulted from
damage to striated muscle, myocardial tissue, or both.
After accounting for the effect of exposure, most of the
unexplained variation in mortality occurred at the level of the
group rather than at the organizational levels of the study, feedlot,
or company depending on the dataset. Moreover, there was almost
no (and at times zero) unexplained variation attributed to
unmeasured company or feedlot level factors. In other words,
the biological association did not vary sufficiently among
companies or feedlots to be detected by the statistical methods
described herein. Group-level factors, therefore, seem to be
important determinants (or modifiers) of mortality and if
discovered, may influence the design of management strategies
to reduce mortality, particularly in pens administered bAA.
Unfortunately, we could not identify any meaningful and
consistent effect modifiers, other than month, in the data and
further research is needed to identify factors that may modify the
observed association between bAA and increased risk of death.
Saliently, the statistical variation of groups is a function of both the
individuals as well as the interaction among the individuals within
the group. In addition to group-level management strategies,
therefore, 2 additional lines of investigation ought to be pursued
and include animal-level factors, such as genetic variation in
response to bAA [28], and how individuals interact to influence
the behavior and potentially the response to bAA of other animals.
The data reported have considerable strengths in that the
number of observations permitted the detection of a change in a
rare event (or events, if one considers the secondary outcomes).
When seeking approval for products, it is extremely uncommon to
have available such numbers to detect rare adverse drug events.
Based on the results observed herein, the number needed to harm,
a measure of extent of exposure required for a bAA-related death,
was approximately 500 animals or 15,000 animal days. In most
reports of well-controlled cattle experiments, the number of
animals included is usually insufficient to speak to an association of
bAA with mortality, given the rarity of death and estimates of the
number needed to harm. As a result, most drug approvals require
some post-approval monitoring, often termed the pharmaco-
epidemiology or Type IV trials, and the self-reporting by patients
of side-effects, either to the company, the FDA, or their doctor, is
part and parcel of a holistic drug regulatory framework.
Furthermore, our data are from commercial cattle fattening
feedlots and as such, provide a degree of validity to the results.
However, the number of companies and feedlots is relatively
limited and consequently, selection bias is possible in that the
decision to provide the data for inclusion in the analyses may have
been influenced by a suspicion of increased mortality associated
with bAA administration.
Despite the potential limitations of the data, we argue that given
the magnitude of the data, and the strength and consistency of the
various measures of effect, both RH and ZH are most likely
causally associated with increased cumulative incidence, incidence
rate, and hazard of death when they are administered in
accordance with the FDA-approved label directions. The excess
deaths attributed to bAA administration, and potentially the
secondary outcomes of illness and occurrence of beef classified as
dark, firm and dry, represent adverse drug events. If so, we believe a
broad and inclusive dialogue that explores the balance between
improved production efficiencies achieved through means such as
bAA [29] and resultant adverse effects on the welfare of animals
we raise for food is needed. This is particularly warranted for those
drugs that are approved solely to improve the efficiencies of
production yet offer no offsetting health benefits to the animals to
which it is administered. For this dialogue to be sufficiently
inclusive, it ought to include a broad collection of stakeholders
such as animal scientists, cattle and beef producers, animal health
specialists, welfarists, ethologists, and consumers.
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